Ma et al. [168] extended these studies using the same CD4 CAR structure but incorporating a natural safety switch based on CAMPATH (Alemtuzumab) to treat CD4+ T-ALL. The gene discussed is CD4; the disease is acute lymphoblastic leukemia.